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Abstract
The updated Vienna Prediction Model for estimating recurrence risk after an unprovoked venous thromboembolism (VTE) has been developed to identify individuals at low risk for VTE recurrence in whom anticoagulation therapy may be stopped after 3 months. We externally validated the accuracy of the model to predict recurrent VTE in a prospective multicenter cohort of 156 patients aged This study was registered at www.clinicaltrials.gov as #NCT00973596.
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Introduction
Unprovoked venous thromboembolism (VTE) is associated with a 5-27% annual risk of recurrence after discontinuation of anticoagulation, [1] [2] [3] [4] and indefinite anticoagulation is recommended if the bleeding risk is low to moderate. 5 However, in one third of patients with unprovoked VTE, the risk of recurrence is so low (<3% per year) that anticoagulant therapy >3 months may not be necessary. 4, 6 Several prediction rules were derived to identify patients with unprovoked VTE who have a low recurrence risk. 4, [7] [8] [9] One is the original Vienna Prediction Model, which was derived in 929 patients (median age 54 years) with a first unprovoked VTE. 11 it is important to avoid extended anticoagulation in elderly patients who have a low recurrence risk.
Study design
This study was performed as part of a prospective multicenter cohort to assess medical outcomes in elderly patients with acute, symptomatic VTE from 9
Swiss university and non-university hospitals (09/2009-12/2013). 12 A detailed description of the study methods has been published previously. 12 Briefly, consenting consecutive patients aged ≥ 65 years with objectively diagnosed, symptomatic DVT or PE were prospectively identified and followed over time. The ethics committee at each participating center approved the study, which followed the Helsinki protocol. or autopsy, as previously described. 12 Three blinded, independent experts adjudicated all recurrences.
We determined the proportion of patients classified as low-risk (lowest quartile of predicted 12-month risk of VTE recurrence) according to the updated Vienna Prediction Model and compared the proportion of VTE recurrence at 12 and 24
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From 6 months between low-and higher-risk patients. We examined the goodness-of-fit of the model at 12 and 24 months using the Hosmer-Lemeshow test. We also assessed the discriminative power of the model by calculating the area under the receiver operating characteristic (ROC) curve for VTE recurrence at 12 and 24 months. Our primary analysis included all patients with unprovoked VTE. In a subgroup analysis, we excluded all patients who had a prior VTE before the index event. Analyses were done using Stata 13 (Stata Corporation, College Station, Texas).
Results and discussion
Overall, 1003 patients were initially enrolled in our cohort. After the exclusion of 394 patients with cancer-related or provoked VTE (14 had hormone therapy), 280 who received anticoagulants beyond 12 months, 167 without D-dimer measurement, and 6 without initial anticoagulation therapy, our final study sample comprised 156 patients with acute unprovoked VTE. A total of 20 patients with unprovoked VTE were excluded because they had recurrent VTE between anticoagulation discontinuation and start of follow-up and thus were still under anticoagulants (n=12) or had no D-dimer measurement (n=8). Of these, 40% were men and 90% had PE/proximal DVT. Overall, there was no age and sex difference between excluded and analyzed patients (data not shown).
Analyzed patients had a median age of 74 years, 41% were women, and 88% had PE or proximal DVT as the initial VTE event (Table) . Low-risk patients were less likely to be men and to have PE/proximal DVT, and had lower D-dimer levels than higher-risk patients.
The proportion of VTE recurrence was 11% (17/156) after 12 months and 17% (26/156) after 24 months. At 12 months, 5% of men had recurrent VTE compared to 19% of women (P=0.02), 11% of patients with PE/proximal DVT compared to 11% of In our study of elderly patients with unprovoked VTE, the updated Vienna Prediction Model did not discriminate between patients who developed recurrent VTE and those who did not. Compared to the derivation population, our patients were older (median age 74 vs. 53 years) and had higher D-dimer levels (median 1022 vs.
356 ng/ml). Whether age itself is independently associated with VTE recurrence is controversial. 3, 4, 7, 13, 14 It is possible that the higher D-dimer levels in elderly patients
could decrease the accuracy of the model, which was derived in younger patients.
Given that the increased recurrence risk in men has been demonstrated predominantly in younger patients (mean age 45-68 years), 4, 9, 15, 16 it is uncertain whether sex is a risk factor for recurrence in the elderly.
Our work has limitations. First, our study was part of a prospective cohort of elderly patients with VTE, which was not primarily designed to validate the updated Vienna Prediction Model. Thus, our sample was relatively small and our study may not have sufficient power to detect a difference in VTE recurrence. Second, because we validated the model in the elderly, our results do not apply to younger patients.
Third, 20 patients with unprovoked VTE had a recurrence between stopping anticoagulation and the start of follow-up and were excluded from analysis (mostly because they were anticoagulated or had missing D-dimer values 
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